US Stock MarketDetailed Quotes

ONCT Oncternal Therapeutics

Watchlist
  • 8.2900
  • +0.0400+0.48%
Close Apr 26 16:00 ET
24.54MMarket Cap-617P/E (TTM)

About Oncternal Therapeutics Company

Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Its product pipeline include Zilovertamab, ONCT-216, ONCT-808 and ONCT-534. The company was founded by David F. Hale and James B. Breitmeyer in September 1997 and is headquartered in San Diego, CA.

Company Profile

SymbolONCT
Company NameOncternal Therapeutics
Listing DateFeb 3, 2004
Issue Price14.50
Founded1997
CEODr. James B. Breitmeyer, M.D.,PhD
MarketNASDAQ
Employees30
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address12230 El Camino Real,Suite 230
CitySan Diego
ProvinceCalifornia
CountryUnited States of America
Zip Code92130
Phone1-858-434-1113
Websitehttp://www.oncternal.com

Company Executives

  • Name
  • Position
  • Salary
  • Dr. James B. Breitmeyer, M.D.,PhD
  • President, Chief Executive Officer and Director
  • 2.41M
  • Rajesh Krishnan
  • Chief Technology Officer
  • --
  • Salim Yazji
  • Chief Medical Officer
  • 962.47K
  • Richard G. Vincent
  • Chief Financial Officer and Treasurer
  • --
  • David F. Hale
  • Chairman of the Board
  • 126.81K
  • Dr. Robert J. Wills, PhD
  • Director
  • 68.21K
  • Dr. Xin Nakanishi, PhD
  • Independent Director
  • 68.21K
  • Dr. Rosemary Mazanet, M.D.,PhD
  • Independent Director
  • 72.21K
  • Dr. Daniel L. Kisner, M.D.
  • Independent Director
  • 80.71K
  • Dr. Charles P. Theuer, M.D.,PhD
  • Independent Director
  • 72.21K
  • William R. Larue
  • Independent Director
  • 80.21K
  • Jill DeSimone
  • Independent Director
  • --
  • Dr. Michael G Carter, Ch.B.,F.R.C.P.,M.D.
  • Independent Director
  • 90.21K
  • Chase C. Leavitt
  • General Counsel and Secretary
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg